[Memorandum to Presidential Advisory Council on HIV and AIDS Research Committee Members from Bruce G. Weniger]

mum " UMMGN N

PHONE NO.: 01483 560074

Jan. 06 1997 11:22PM PO6

new operation from a green-field site.
* Expenditure of the order of $300million per annum for over 20 years
should be the basis on which the institute is funded. This money should
emanate from governmental sources as a redeployment of public funds in
the public interest.
* An institute could be designed, built, staffed and functioning, were a clear
go-ahead given and finances provided up-front within 12-18 months.
* Final staffing levels would be of the order of 1,000 professional and
support staff. (Approximately, $50,000 per head salary plus $100,000
overhead per staff member) plus $150 million for the provision of facilities
and experiments in primates and humans) The proportions of the
expenditure would change as the site and the experimental program
required.
* Industry, in any shape or form, should not be involved with the direction of
the work of this institute. It is possible that from time to time there would
be spin-off products which could be further developed and commercialised
by industry; this should be accomplished by a specialised technology
transfer unit either based on in-house personnel or specialist operations
from outside,
* It may be that industry would be asked to tender for the production and
distribution of the vaccine when such had been well enough defined for the
production of the necessary SOPs.
* The work and operation of the institute should be monitored by a special
commission of the government from time to time with a remit of
determining whether the public monies involved have been well used.* Were the institute to successful in its goal then it could be redirected to
another vaccine target (malaria, tuberculosis, schistosomiasis etc) assuming
that such vaccines have not already been discovered by then.
5. Further Considerations
While I have made some outline suggestions as to how it is possible to proceed with a
project which would yield a vaccine protective against AIDS, I cannot give 100%
assurances that the outcome will be successful; I can assert however that it is my firm
belief that an operation of this sort would be the quickest and surest way to the objective
of a vaccine protective against AIDS; it may even be the least expensive.

5